Yahoo
    OTC Markets OTCPK - Delayed Quote USD

    WuXi Biologics (Cayman) Inc. (WXXWY)

    12.43 +1.52 (+13.93%)
    As of 12:55:13 PM EST. Market Open.
    Loading Chart for WXXWY
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence

    WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
    PR Newswire 15h ago
    Missed WuXi Biologics' Run? Here's The Bet Holders Made

    Missed WuXi Biologics' Run? Here's The Bet Holders Made
    Simply Wall St. 1d ago
    Fresenius and WuXi Bio team up in 37-strong biosimilar development deal

    Fresenius and WuXi Bio team up in 37-strong biosimilar development deal
    Pharmaceutical Technology 2d ago
    Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

    Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
    PR Newswire 2d ago
    WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

    WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026
    PR Newswire 14d ago
    Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

    Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?
    Simply Wall St. 15d ago
    WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

    WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence
    PR Newswire 21d ago
    Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

    Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
    GlobeNewswire 1mo ago
    WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

    WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
    PR Newswire 1mo ago
    WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

    WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
    PR Newswire 1mo ago
    Big Pharma Is Pouring Billions Into China’s Biotechs

    Big Pharma Is Pouring Billions Into China’s Biotechs
    Barrons.com 1mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: